Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

Documenti analoghi

• Dose reduction of biologics in patients with plaque psoriasis: a review
  di: C. A. M. van Riel, et al.
  Pubblicazione: (2024-03-01)
• Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial
  di: Selma Atalay, et al.
  Pubblicazione: (2022-07-01)
• Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
  di: L.S. van der Schoot, et al.
  Pubblicazione: (2023-12-01)
• Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study
  di: Lara S. van der Schoot, et al.
  Pubblicazione: (2021-10-01)
• Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
  di: Marloes E. van Muijen, et al.
  Pubblicazione: (2022-08-01)